ALECENSA Drug Use Surveillance
Phase of Trial: Phase IV
Latest Information Update: 08 Sep 2017
At a glance
- Drugs Alectinib (Primary)
- Indications Lung cancer
- Focus Adverse reactions
- Sponsors Chugai Pharmaceutical
- 06 Sep 2017 Status changed from active, no longer recruiting to completed.
- 01 Jul 2015 Status changed from recruiting to active, no longer recruiting as per University Hospital Medical Information Network - Japan.
- 10 Sep 2014 New trial record